Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

EST Cathie Wood’s ARK Investment buys 54.4K shares of Qualcomm (QCOM) todayMaximize Your Portfolio with Data Driven Insights:Leverage the ...

In a report released yesterday, Mark Lipacis from Evercore ISI maintained a Hold rating on Qualcomm (QCOM – Research Report), with a price ...

US stocks were mixed on Thursday in anticipation of Amazon's quarterly results, as investors assessed the earnings season so ...

Wall Street drifted to a mixed close as drops for Ford Motor and Qualcomm worked against buoyant fashion and cigarette stocks. The S&P 500 rose 0.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Investing.com-- The S&P 500 gave up gains Thursday, as investors assessed a deluge of corporate earnings as well as more ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...